WAYLAND, Mass.--(BUSINESS WIRE)--A recent study published in The Journal of Lasers in Surgery and Medicine shows that the new micropulse technology of Candela Corporation’s (NASDAQ: CLZR) flagship Vbeam® Pulsed Dye Laser – the Perfecta™, improves efficacy to safely treat vascular and epidermal pigmented lesions while reducing or eliminating undesired side effects such as purpura. The Vbeam Perfecta technology provides patients options when considering skin rejuvenation, fading of sun and age spots, removal of leg and facial veins, treatment of rosacea, dyschromia and more.
